Abstract BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd?) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd? lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd? lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd? lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd? lesions in patients from the BG-12 group and 221 Gd? lesions in patients from the placebo group. The percentage of Gd? lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p \ 0.0001). In addition to
Introduction
BG-12 is an oral formulation of dimethyl fumarate (DMF) currently in clinical development for relapsing forms of multiple sclerosis (MS). Preclinical studies using in vitro cell cultures and in vivo experimental autoimmune encephalomyelitis models have demonstrated anti-inflammatory and neuroprotective effects of DMF and its primary metabolite, monomethyl fumarate [1, 2] . DMF and monomethyl fumarate activate the nuclear factor erythroid-2-related factor (Nrf2) transcriptional pathway [3] , which is central to oxidative and metabolic stress response, essential for immune homeostasis, and implicated as a regulator of myelin maintenance in the central nervous system [4] [5] [6] [7] .
In a double-blind, dose-ranging, phase 2b study of BG-12 in patients with relapsing MS, 257 patients were randomized to receive BG-12 at rates of 120 mg once daily (qd), 120 mg three times daily (tid; 360 mg/day), 240 mg tid (720 mg/day), or placebo for 24 weeks during an initial placebo-controlled treatment period [8] . Treatment with 240 mg BG-12 tid resulted in a 69% reduction in total mean number of new gadolinium-enhancing (Gd?) lesions on MRI scans from weeks 12 to 24 compared with placebo (4.5, BG-12; 1.4, placebo; p \ 0.001). BG-12 at 240 mg tid also reduced the number of new/enlarging T2-hyperintense lesions by 48% (p \ 0.001) and new T1-hypointense lesions by 53% (p = 0.014) compared with placebo. This greater effect on T1-hypointense lesions versus T2-hyperintense lesions is unusual because disease-modifying therapies typically have a greater impact on T2-hyperintense lesions; thus, further investigation was warranted.
Some, but not all, Gd? lesions evolve to persistent T1-hypointense lesions seen on T1-weighted spin echo images [9] . The presence of persistent nonenhancing T1-hypointense lesions on brain magnetic resonance imaging (MRI) scans of patients with MS is considered a putative marker for myelin and axonal damage [10] . In this retrospective analysis of the phase 2b study, we investigate whether BG-12 affected the evolution of new Gd? lesions to persistent T1-hypointense lesions in patients with relapsing MS.
Patients and methods

Patients and study design
The 240 mg BG-12 tid group was the only BG-12 treatment group included in this retrospective analysis because it was the BG-12 study arm that showed significant and greatest reduction in Gd? lesions, T2-hyperintense lesions, and T1-hypointense lesions compared with placebo. Full study methods have been published elsewhere [8] . Briefly, this double-blind, parallel-group, dose-ranging phase 2b study of BG-12 enrolled 257 patients from 43 centers in the Czech Republic, Germany, Hungary, the Netherlands, Poland, Russia, Sweden, Switzerland, Turkey, and the United Kingdom. During an initial placebo-controlled treatment period, patients were equally randomized to receive BG-12 at 120 mg qd, 120 mg tid, 240 mg tid, or placebo for 24 weeks. Key inclusion criteria were patient age between 18 and 55 years (inclusive); a diagnosis of relapsing-remitting MS according to the McDonald criteria (nos. 1-4) [11] ; a baseline Expanded Disability Status Scale score between 0.0 and 5.0 (inclusive) [12] ; and at least one relapse within 12 months before randomization and a brain MRI consistent with MS, or Gd? lesions on MRI performed within 6 weeks of randomization. Patients were excluded if they received mitoxantrone or cyclophosphamide within 1 year; cyclosporine, azathioprine, methotrexate, natalizumab, intravenous immunoglobulin, plasmapheresis, or other investigational drugs within 6 months; glatiramer acetate or interferon beta within 3 months; or corticosteroids (oral or intravenous), 4-aminopyridine, or related products within 30 days of randomization.
Standard protocol approvals and registrations
The study protocol was approved by independent ethics committees, and the study was conducted in accordance with the Declaration of Helsinki, International Conference of Harmonisation and Good Clinical Practice guidelines, and local regulations. Informed consent was provided by all patients enrolled in the study. The study was registered on ClinicalTrials.gov (identifier NCT00168701).
MRI acquisition protocol and analysis
Brain MRI scans were obtained at baseline and weeks 4, 8, 12, 16, 20 , and 24 using a system operating at 1.0 or 1.5 tesla. A dual-echo fast spin echo sequence (repetition time = 2,500-3,300 ms; short echo time = 10-40 ms; long echo time = 80-100 ms) was used to obtain proton density and T2-weighted images. A conventional spin echo sequence (repetition time = 500-700 ms; echo time = 10-20 ms) was applied for obtaining T1-weighted images (before and after the injection of 0.1 mmol/kg gadolinium contrast medium) in the corresponding spatial location to the fast spin echo scans. For all MRI sequences, 46 contiguous 3 mm thick axial slices were acquired using a field view of 250 mm, a reconstructed image matrix of 256 9 256, and an in-plane spatial resolution of 0.97 9 0.97 mm.
MRI analysis
After completion of the clinical study, a retrospective analysis was performed using MRI scans obtained from patients assigned to the 240 mg BG-12 tid and placebo groups in the phase 2b study. Examination of all scans was performed by personnel (DGM, KS, TAY) blinded to the patients' treatment group assignment and clinical details. Lesions were analyzed by visual inspection of all scans using electronic data where available and hard copy images where satisfactory electronic data were not available. All new Gd? lesions were identified on scans from weeks 4, 8, and 12. To confirm that the new Gd? lesions also were de novo T2 lesions, the prior MRI scan was reviewed. Regions of new gadolinium enhancement in pre-existing T2 lesions were not included in the analysis because there already may have been tissue damage, which would influence the likelihood of subsequent T1 hypointensity in these regions. Gd? lesions were classified as large ([5 mm) or small (B5 mm) based on measurement of their largest diameter. This cutoff criterion ([5 mm and B5 mm) was chosen for this analysis because it was used in similar analyses for other MS therapeutics [13, 14] . The status of the new Gd? lesions was evaluated on postcontrast T1-weighted scans obtained at week 24 and reported as still Gd? or no longer enhancing. Nonenhancing lesions were further classified as T1-isointense lesions or T1-hypointense lesions relative to the surrounding normalappearing white matter. The size of the nonenhancing lesions ([5 mm or B5 mm) also was recorded.
Statistical analysis
Patients in the placebo and 240 mg BG-12 tid arms who had at least one Gd? lesion from weeks 4 to 12 were included in the analysis. For each patient, the following were calculated: cumulative number of new Gd? lesions on MRI scans from weeks 4 to 12, cumulative number of T1-hypointense lesions that formed from the Gd? lesions at week 24, and proportion of Gd? lesions from weeks 4 to 12 that evolved to T1-hypointense lesions at week 24. For each treatment group, the following were calculated: total number of new Gd? lesions from weeks 4 to 12, total number and proportion of Gd? lesions that evolved to T1-hypointense lesions at week 24, and number and proportion of large ([5 mm) and small (B5 mm) Gd? lesions and T1-hypointense lesions. Summary statistics were used to describe these data.
At the lesion level, a logistic regression model based on generalized estimating equations which take into account within-patient correlation of lesions, was used to analyze and compare the probability of evolution from a new Gd? lesion to a T1-hypointense lesion between the BG-12 and placebo groups. For the primary analysis, the model was adjusted for baseline number of Gd? lesions. In additional analyses, the model was adjusted for baseline number of Gd? lesions, years since disease onset, and relapses in the previous 3 years, or baseline number of Gd? lesions, years since diagnosis, and number of relapses in the previous 3 years as categorical variables. The odds ratio (OR) of lesion evolution from Gd? to T1-hypointense was computed using the placebo group as a reference.
Results
The 24 week, placebo-controlled period of the BG-12 phase 2b clinical study included 65 patients in the placebo group and 63 patients in the BG-12 240 mg tid group. Of these, twice as many patients in the placebo group (n = 38) than in the BG-12 group (n =18) had one or more Gd? lesion at weeks 4-12 and were included in the retrospective analysis. The demographic and baseline patient characteristics of the present study cohort were similar to those of the entire study population (Table 1 ) [8] . At baseline, the mean number of Gd? lesions was slightly higher in the BG-12 group (3.3 in 18 patients) compared with placebo (2.7 in 38 patients) (p = not significant). Because we selected patients who had one or more Gd? lesions from weeks 4 to 12, it was not surprising that the mean number of baseline Gd? lesions in the present retrospective analysis cohort was slightly higher than that for the entire phase 2b study population in the placebo (2.7 in the present analysis vs. 1.6 in the entire phase 2b study population) and BG-12 (3.3 in the present analysis vs. 1.3 in the entire phase 2b study population) groups.
When analyzing these data at the patient level (i.e., proportion of Gd? lesions that converted to T1-hypointense lesions was calculated for each patient and summary statistics for both treatment groups were tallied), the 18 patients in the BG-12 group had a higher mean number of Gd? lesions (8.2) than the 38 patients in the placebo group (5.8) on scans at weeks 4, 8, and 12 (Table 2) . However, the mean number of T1-hypointense lesions formed from the Gd? lesions by week 24 was similar in the BG-12 and placebo groups (2.3, BG-12; 2.6, placebo) (p = not significant). This result is due to the fact that the mean proportion of Gd? lesions that evolved to T1-hypointense lesions per patient was 0.29 in the BG-12 group compared with 0.41 in the placebo group; this outcome represents a 29% reduction in evolved Gd? lesions with BG-12 treatment when analyzing lesions at the patient level.
When analyzing these data at the lesion level (i.e., each lesion is counted as one observation in the analysis), 147 new Gd? lesions from the 18 patients in the BG-12 group and 221 Gd? lesions from the 38 patients in the placebo group were tracked on scans from weeks 4 through 12 and analyzed at week 24 to see if they had evolved into a T1 hypointensity ( Fig. 1; Table 2 ). The proportion of total Gd? lesions that evolved to T1-hypointense lesions was 0.29 in the BG-12 group versus 0.44 in the placebo group ( Fig. 1; Table 2 ); this result represents a 34% reduction when analyzing data at the lesion level with BG-12 treatment compared with placebo. The OR for the evolution of new Gd? lesions to T1-hypointense lesions for BG-12 compared with placebo was 0.51 (95% confidence interval [CI] 0.43, 0.61; p \ 0.0001). When the model was adjusted for years since disease onset and relapses in the previous 3 years in addition to baseline Gd? lesions, the OR was 0.40 (95% CI 0.25, 0.66; p = 0.0003). Similarly, when the model was adjusted for years since diagnosis and relapses in the previous 3 years in addition to baseline Gd? lesions, the OR was 0.49 (95% CI 0.27, 0.88; p = 0.0171). Exclusion of three patients (two from the placebo group and one from the BG-12 group) who had relatively large numbers (C40) of Gd? lesions from the analysis did not influence this result (OR 0.65; 95% CI 0.47, 0.89; p = 0.008).
When analyzing these data by lesion size, 40 (27%) of the Gd? lesions in the BG-12 group and 76 (34%) of the Gd? lesions in the placebo group were classified as large ([5 mm) on the basis of lesion diameter (Fig. 1) . In placebo-treated patients, the probability of large Gd? lesions becoming T1 hypointense was higher than that for small 20] ). There was a trend for fewer large Gd? lesions to evolve to T1-hypointense lesions in the BG-12 treatment arm compared with placebo (OR 0.62; 95% CI 0.39, 1.01; p = 0.055). The probability of small Gd? lesions evolving to T1-hypointense lesions was significantly lower with BG-12 treatment compared with placebo (OR 0.37; 95% CI 0.30, 0.45; p \ 0.0001). Overall, the proportion of large T1-hypointense lesions that evolved from any Gd? lesions (large or small) was not different in the BG-12-treated group (10%) compared with the placebo group (15%) (p = 0.251).
Discussion
In this retrospective analysis of a phase 2b study, treatment with 240 mg BG-12 tid orally for 24 weeks reduced the probability of evolution of new Gd? lesions to T1-hypointense lesions compared with placebo in patients with relapsing MS (OR 0.51; 95% CI 0.43, 0.61; p \ 0.0001). Even when the model was adjusted for additional baseline factors, including disease duration and relapse activity in the previous 3 years, the difference between the BG-12 and placebo groups remained significant (p = 0.0171).
A potential mechanism for reduced evolution from Gd? to T1 hypointensity is a reduction in the size of Gd? lesions because larger Gd? lesions are more likely to become T1 hypointense (as seen in the placebo arm of the present study and in a previous study [13] ). Although the proportion of large Gd? lesions was slightly lower in BG-12-treated versus placebo-treated patients (27 vs. 34%), this mechanism does not explain the reduced conversion to T1 hypointensity, which was evident for small and large Gd? lesions, though more so for small lesions (63% reduction in odds of lesion evolution for small Gd? lesions [p \ 0.001] vs. 38% reduction for large lesions [p = 0.055]). The development of new Gd? lesions on T1-weighted MRI indicates blood-brain barrier breakdown and suggests active inflammation at the site of enhancement [15] . Most new Gd? lesions are hypointense on unenhanced T1-weighted images during the acute phase, but many of these lesions become T1 isointense during follow-up [9] ; most remain visible as high-signal lesions on T2-weighted images. Histopathological studies have shown that persistent T1-hypointense lesions are less likely to remyelinate [16] and are associated with greater tissue matrix damage, including axonal loss, compared with T1-isointense lesions [10, 17, 18] . Thus, therapeutic agents that limit the evolution of new Gd? lesions to T1-hypointense lesions are likely to confer benefit to patients with MS by reducing the extent of axonal damage at the lesion site. Similar to BG-12, some currently approved MS disease-modifying therapies affect the evolution of Gd? lesions to T1-hypointense lesions [14, 19] . In patients treated with natalizumab, the proportion of Gd? lesions that evolved to T1-hypointense lesions was 15% (vs. 25% in the placebo group, p = 0.045) and the OR of evolution from Gd? to T1-hypointense lesions was 0.48 (95% CI 0.24, 0.94; p = 0.031) [14] . Glatiramer acetate has also been shown to reduce the evolution of Gd? lesions to T1-hypointense lesions compared with placebo (16% vs. Odds ratio for probability of evolution from Gd+ lesions to T1-hypointense lesions (95% CI), BG-12 vs. placebo Proportion of large Gd+ lesions evolved to T1-hypointense lesions at week 24 0.63 0.52
Odds ratio for probability of evolution from large Gd+ lesions to T1-hypointense lesions (95% CI), BG-12 vs. placebo 31%, p = 0.002) [19] . Although one study showed no such effect for interferon beta-1b versus placebo [13] , a recent study reported fewer Gd? lesions evolving to T1-hypointense lesions with interferon beta-1b compared with glatiramer acetate [20] . Anti-inflammatory effects of oral fumarates have been demonstrated in preclinical and clinical studies [1, 21] and were the initial reason for the development of BG-12 as a therapeutic agent in MS [1] . BG-12 can activate the Nrf2 transcriptional pathway in cultured cells [3] . The Nrf2 pathway is known to be a critical regulator of oxidative and metabolic stress response, and activation of this pathway confers neuroprotective effects. Specifically, scientific evidence suggests that Nrf2 mediates its protective effects by increasing the transcription of genes coding for detoxification enzymes and improving neuronal survival [22] [23] [24] , maintaining the integrity of myelin [7] , and protecting the blood-brain barrier [25] .
A recent analysis evaluated the feasibility of using the evolution of contrast-enhancing lesions to T1-hypointense lesions as a marker of protection against subsequent axonal loss of treatment. The authors concluded that 200 patients per treatment arm would be required to detect a treatment effect of 50% [26] . Given these results, our analysis may be underpowered to detect a treatment effect; however, the greater effect of 240 mg BG-12 tid on T1-hypointense lesions compared with T2-hyperintense lesions observed in the overall phase 2b study supports the results of the present retrospective analysis and warrants further investigation.
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